Caveat Emptor

The UK's Times Online reports on the growing market of companies like 23andMe, kicking off with this straight-to-the heart statement: "Leading genetic testing companies are providing clients with widely divergent and inaccurate predictions of their chances of developing serious diseases." The author has used the services of 23andMe, DecodeMe, and British provider GeneticHealth, getting in return "contradictory assessments of the risk I faced of developing illnesses, including Alzheimer's and glaucoma, and a confused verdict on my risk of suffering heart problems."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.